Skip to Content


Active Substance: pegloticase
Common Name: pegloticase
ATC Code: M04AX02
Marketing Authorisation Holder: Crealta Pharmaceuticals Ireland Limited
Active Substance: pegloticase
Status: Withdrawn
Authorisation Date: 2013-01-08
Therapeutic Area: Gout
Pharmacotherapeutic Group: Antigout preparations

Therapeutic Indication

Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

The marketing authorisation for Krystexxa has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.